The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 19, 2016

Filed:

Jan. 20, 2011
Applicants:

David V. Gold, Metuchen, NJ (US);

David M. Goldenberg, Mendham, NJ (US);

Inventors:

David V. Gold, Metuchen, NJ (US);

David M. Goldenberg, Mendham, NJ (US);

Assignee:

Immunomedics, Inc., Morris Plains, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 47/48 (2006.01); A61K 51/04 (2006.01); A61K 51/08 (2006.01); A61K 51/10 (2006.01); B82Y 5/00 (2011.01); B82Y 15/00 (2011.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48746 (2013.01); A61K 51/0406 (2013.01); A61K 51/0491 (2013.01); A61K 51/08 (2013.01); A61K 51/088 (2013.01); A61K 51/109 (2013.01); B82Y 5/00 (2013.01); B82Y 15/00 (2013.01); C07K 16/303 (2013.01); C07K 16/3092 (2013.01); C07K 16/44 (2013.01); G01N 33/57438 (2013.01); G01N 33/57488 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01);
Abstract

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.


Find Patent Forward Citations

Loading…